Search research articles
Contact Us
Filters
Showing results (591-600 of 1,117) with videos related to
Page
of 112
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Pasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Molecular Therapy. Oncology
|
June 30, 2026
Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC
Gabriella Antignani, Michaela Feodoroff, Jacopo Chiaro, et al.
European Urology Oncology
|
July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Pasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
T R Shenoy, G Boysen, M Y Wang, et al.
Future Oncology (London, England)
|
April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Future Oncology (London, England)
|
June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M P Kolinsky, P Rescigno, D Bianchini, et al.
Page
of 112
Search research articles
Search
Showing results (591-600 of 1,117) with videos related to
Sort By:
Page
of 112
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Pasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Molecular Therapy. Oncology
|
June 30, 2026
Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC
Gabriella Antignani, Michaela Feodoroff, Jacopo Chiaro, et al.
European Urology Oncology
|
July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Pasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
T R Shenoy, G Boysen, M Y Wang, et al.
Future Oncology (London, England)
|
April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Future Oncology (London, England)
|
June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M P Kolinsky, P Rescigno, D Bianchini, et al.
Page
of 112